Skip to content

Symfony/Synergy IOL Combination Outcomes

Evaluating A Novel Strategy: The Synergy IOL Mixed and Matched With the Symfony With Intelilight

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05604781
Enrollment
41
Registered
2022-11-03
Start date
2022-10-17
Completion date
2023-05-16
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral Cataract, Presbyopia

Brief summary

Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Some may have already enjoyed freedom from glasses and would like to continue after the cataracts are removed. Different options are available. These options include: mono-vision and presbyopia correcting intraocular lenses (IOL). Presbyopia correcting IOLs include accommodative, multifocals and extended depth of focus (EDOF) IOLs. In a previous study that evaluated the visual outcomes of an EDOF IOL when combined with a multifocal IOL with a +3.25 D add in patients with or without astigmatism undergoing routine cataract surgery showed good outcomes with high patient satisfaction and less dependance on glasses for intermediate and near activities. As technology evolves, new lens models are available in the market. The purpose of this study is to evaluate the latest EDOF and a hybrid multifocal lenses when combined.

Interventions

DEVICESymfony & Synergy IOL combination

The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.

Sponsors

Science in Vision
CollaboratorOTHER
Center For Sight
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subject is undergoing bilateral lens extraction with intraocular lens implantation of the Symfony with InteliLight in the dominant eye and a Synergy in the non-dominant eye. 2. Gender: Males and Females. 3. Age: 50 years and older. 4. Willing and able to provide written informed consent for participation in the study 5. Willing and able to comply with scheduled visits and other study procedures. 6. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 2 to 30 days between surgeries 7. Subjects who require an IOL power in the range of +5.00 D to +34.0 D only. 8. Subjects who require a toric IOL up to +3.75 D at the IOL plane (2.57 D corneal plane). 9. Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

Exclusion criteria

1. Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc. 2. Uncontrolled diabetes. 3. Use of any systemic or topical drug known to interfere with visual performance. 4. Contact lens use during the active treatment portion of the trial. 5. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis. 6. Clinically significant corneal dystrophy 7. History of chronic intraocular inflammation. 8. History of retinal detachment. 9. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules. 10. Previous intraocular surgery. 11. Previous corneal refractive surgery (i.e. LASIK, photorefractive keratectomy, radial keratotomy). 12. Previous keratoplasty 13. Severe dry eye 14. Pupil abnormalities 15. Anesthesia other than topical or peribulbar anesthesia (i.e. retrobulbar, general, etc). 16. Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results. 17. Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.

Design outcomes

Primary

MeasureTime frame
Binocular Defocus Curve3 months

Secondary

MeasureTime frameDescription
Patient Satisfaction Questionnaire3 monthsPercentage for participants who are completely or mostly satisfied with their overall vision will be assessed
Spectacle Independence for Near Activities Questionnaire3 monthsPercentage of participants reporting the need to wear glasses all the time for near activities will be assessed.

Countries

United States

Participant flow

Participants by arm

ArmCount
Symfony & Synergy IOL Combination
Symfony & Synergy IOL combination: The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
37
Total37

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event1
Overall StudyLost to Follow-up3

Baseline characteristics

CharacteristicSymfony & Synergy IOL Combination
Age, Continuous68.6 years
STANDARD_DEVIATION 6.3
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
37 Participants
Region of Enrollment
United States
37 participants
Sex: Female, Male
Female
27 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 37
other
Total, other adverse events
0 / 37
serious
Total, serious adverse events
0 / 37

Outcome results

Primary

Binocular Defocus Curve

Time frame: 3 months

ArmMeasureGroupValue (MEAN)Dispersion
Symfony & Synergy IOL CombinationBinocular Defocus Curve+0.50 D-0.05 logMARStandard Deviation 0.08
Symfony & Synergy IOL CombinationBinocular Defocus Curve0.00 D-0.08 logMARStandard Deviation 0.12
Symfony & Synergy IOL CombinationBinocular Defocus Curve-0.50 D-0.05 logMARStandard Deviation 0.09
Symfony & Synergy IOL CombinationBinocular Defocus Curve-1.00 D-0.04 logMARStandard Deviation 0.1
Symfony & Synergy IOL CombinationBinocular Defocus Curve-1.50 D-0.03 logMARStandard Deviation 0.13
Symfony & Synergy IOL CombinationBinocular Defocus Curve-2.00 D0.04 logMARStandard Deviation 0.13
Symfony & Synergy IOL CombinationBinocular Defocus Curve-2.50 D0.07 logMARStandard Deviation 0.14
Symfony & Synergy IOL CombinationBinocular Defocus Curve-3.00 D0.14 logMARStandard Deviation 0.14
Symfony & Synergy IOL CombinationBinocular Defocus Curve+1.00 D0.07 logMARStandard Deviation 0.1
Secondary

Patient Satisfaction Questionnaire

Percentage for participants who are completely or mostly satisfied with their overall vision will be assessed

Time frame: 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Symfony & Synergy IOL CombinationPatient Satisfaction Questionnaire31 Participants
Secondary

Spectacle Independence for Near Activities Questionnaire

Percentage of participants reporting the need to wear glasses all the time for near activities will be assessed.

Time frame: 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Symfony & Synergy IOL CombinationSpectacle Independence for Near Activities Questionnaire4 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026